Suicide gene therapy is based on the introduction into tumor cells of a viral or a bacterial gene, which allows the conversion of a non-toxic compound into a lethal drug. Although suicide gene therapy has been successfully used in a large number of in vitro and in vivo studies, its application to cancer patients has not reached the desirable clinical significance.
Introduction
Chemotherapy, radiotherapy and surgery constitute the conventional treatments for cancer, and among these, complete surgical resection is still the most effective approach to treat cancer patients. However, these patients often exhibit advanced stage tumors limiting the possibility of surgery or favouring relapses after resection. In addition, the recent discovery in a large number of cancers of a rare population of cells with stem cell-like properties called «cancer stem cells» (CSCs), which fuel tumor growth and exhibit different features compared to differentiated tumor cells, appears as a new challenge for cancer treatment. Therefore, as the majority of cancers remain resistant to the current therapeutic options, the development of more efficient strategies is still urgent [1; 2] .
Gene therapy appears as a good alternative and holds a great promise for the treatment of various diseases including cancer, as evidenced by the significant number of recently reported clinical trials [3; 4; 5; 6; 7; 8] . In cancer gene therapy, different approaches can be used such as mutation correction; enhancement of the immune response against tumor cells; RNA interference, targeted lysis of tumor cells using selective replicative viruses; anti-angiogenic and suicide gene therapies [9] .
In this review, we will focus on suicide gene therapy, summarizing the different suicide gene systems and gene delivery vectors addressed to cancer, giving particular emphasis to recently developed systems and associated bystander effects. In addition, we will review the different strategies that have been used in combination with suicide gene therapy and provide some insights into the future directions of this approach.
The concept of suicide gene therapy and the different suicide systems
Suicide gene therapy is based on the introduction into tumor cells of a viral or a bacterial gene, which allows the conversion of a non-toxic compound into a lethal drug (Figure 1 ).
Among the large number of suicide systems that have been reported (Table I) , the herpes simplex virus thymidine kinase gene (HSV-tk) with ganciclovir (GCV) as prodrug and the cytosine deaminase gene (CD) of E. coli, which converts the non-toxic antifungal agent 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU), are the most extensively studied. These two systems will be described in more detail.
The TK/GCV suicide system
HSV-tk/GCV is one of the most promising "suicide" gene therapy systems. The expression of the HSV-tk gene leads to the production of viral thymidine kinase that metabolizes GCV to ganciclovir monophosphate. Cellular kinases then convert monophosphorylated GCV into ganciclovir triphosphate. As the latter compound is an analogue of deoxyguanosine triphosphate, inhibiton of DNA polymerase and/or incorporation into DNA occurs causing chain termination and tumoral cell death [10; 11; 12] .
It was demonstrated that erroneous GCV triphosphate incorporation into DNA results in Sphase delay, as well as G2-phase arrest by the activation of 3' exonuclease and postreplicative endonuclease repair mechanisms [13; 14; 15; 16] . As a result of GCV-induced cell cycle arrest, Wei et al. found that apoptosis rather than a direct chemical effect was involved in HSV-tk-transduced B16F10 melanoma cell death [17] . Beltinger et al., reported that TK/GCV-induced apoptosis in cultured human neuroblastoma cells involves accumulation of p53, translocation of CD95 to the cell surface mediated by p53 and CD95-L-independent formation of a death-inducing signaling complex containing Fas-associated death domain protein (FADD) and caspase-8 [18] . In contrast, Tomicic et al. and Fischer et al. showed that, upon application of HSV-tk suicide gene therapy in Chinese hamster ovary and glioma cell lines, GCV-induced apoptosis occurred mainly by activating the mitochondrial damage pathway, in which a decline in Bcl-2 levels was observed [19; 20] . Therefore, caspase activation may be a consequence of different initiation events depending on the cell type. In a recent study, the relevance of the cell cycle control towards the sensitivity of pancreatic tumour cells to the cytotoxicity induced by the HSV-tk/GCV system was demonstrated, since a Chk1 activation was associated with a greater HSV-tk/GCV extent of cell death [21] .
In vivo anti-tumor activity of the TK/GCV system has been demonstrated in several carcinoma animal models, including leukemia [22] , glioma [23; 24] , bladder cancer [25] , intrahepatic metastasis of liver cancer [26] , colon adenocarcinoma [27] , and oral cancer, [28; 29] .
The promising results achieved in the pre-clinical studies with the HSV-tk/GCV system led to its application in a number of clinical trials towards different types of cancer [30; 31; 32; 33; 34; 35] . In a prospective phase I/II clinical study, Voges et al. treated patients suffering from recurrent glioblastoma multiforme with HSV-1-tk gene-bearing cationic liposomal vector and systemic ganciclovir and observed a therapeutic benefit in some of the patients. The results of this phase I/II study demonstrated the feasibility and safety of this therapeutic strategy [31] . In a more recent study, Nasu et al. conducted a phase I clinical trial addressed to hormonerefractory prostate cancer in 8 patients, which involved the administration of HSV-tk mediated by adenovirus followed by ganciclovir. In 5 patients, a clear decrease of prostatespecific antigen (PSA) values was observed, confirming the safety profile and possibility of clinical response at the surrogate marker level [32] .
Given the successful results obtained with the HSV-tk/GCV system in humans, some studies have pursued to phase III clinical trials [30] . 
The CD/5-FC suicide system
The CD enzyme, found in several bacteria and fungi but not in mammalian cells, catalyses the hydrolytic deamination of cytosine into uracil. It can therefore convert the non-toxic prodrug 5-FC to 5-FU, which is then transformed by cellular enzymes into potent pyrimidine antimetabolites (5-FdUMP, 5-FdUTP, 5-FUTP). Three pathways are involved in the induced cell death: thymidylate synthase inhibition, formation of (5-FU) RNA and of (5-FU) DNA complexes [55] .
Similarly to HSV-tk/GCV system, apoptosis is also involved in the mechanism of cytotoxicity induced by the CD/5-FC suicide system [20] . It was reported that in glioma cells, the mitochondrial pathway is involved in the process of cell death induced by both suicide gene systems, while p53 and death receptors are not implicated in such process. Although it was
shown that the cytotoxicity induced by the HSV-tk/GCV and CD/5-FC suicide systems follow a mitochondrial pathway, the mechanisms of modulation of Bcl-2 proteins were found to be different [20] ). Finally, a study of Negroni et al. suggested that the activation of heat shock protein 90-beta by phosphorylation in CD-expressing colon carcinoma cells upon 5-FC treatment, might contribute to tumor regression and tumor immunogenicity [56] .
5-FU has been widely used in cancer chemotherapy but high doses are generally required for tumor response. This suicide system results in tumor targeted chemotherapy and allows bypassing the toxic side effects generally associated to systemic 5-FU chemotherapy. The CD gene has been cloned from Escherichia coli [57] and has been shown in a number of in vitro studies to confer mammalian cell sensitivity to 5-FC.
The CD/5-FC system has been further improved in several studies by the inclusion of the uracil phosphoribosyltransferase (UPRT) gene allowing the conversion of 5-FU to 5-fluorouridine monophosphate, the first step of its pathway to activation [58] . Importantly, this CD-UPRT/5-FC suicide system was shown to be effective against 5-FU-resistant human primary cancer cells [59] .
Finally, a bifunctional chimeric protein designated FCU1, combining the yeast enzymatic activities of CD and uracil phosphoribosyltransferase was shown to highly increase CD activity [60] .
In vivo anti-tumor activity of the CD/5-FC combination has been demonstrated in several animal models, including fibrosarcomas [61] , carcinomas [62; 63; 64; 65; 66] , gliomas [67] and metastatic formations of different origin [68; 69] .
A number of clinical trials have been reported using the CD/5-FC system, although its application in the clinic has been limited [35; 70; 71; 72] . The first clinical trial using the CD/5-FC system was performed in breast cancer patients and involved specific targeting to the erbB-2 oncogene overexpressed in this type of cancer. The authors showed that their approach was safe and selective to erbB-2-positive tumor cells [70] .
In another study, Nemunaitis et al. found to be functional [71] .
A different delivery system, which consisted in the use of an oncolytic adenovirus containing a CD/HSV-1 TK fusion gene, was applied in a phase I clinical trial in 75 patients with newly diagnosed, intermediate-to high-risk prostate cancer [72] . It was found that the transgene expression persisted in the prostate for up to 3 weeks after the adenovirus injection. A combination of this therapeutic system with conventional-dose three-dimensional conformal radiation therapy resulted in significant declines in PSA in all patients, and this combined approach was shown to be safe [72] .
Delivery systems

Viral vectors
Because viruses have evolved natural mechanisms to deliver their genomes into cells, they are excellent vectors to deliver foreign DNA. These vectors are designed by replacing nonessential genes involved in viral replication or pathogenic protein production with foreign therapeutic genes. Production of recombinant viral vectors is achieved by providing in trans the non-essential genes, either integrated into the genome of a packaging cell line or in a plasmid. The choice of viral vector depends on several parameters such the characteristics of the cancer type and the therapeutic strategy. The commonly used viral vectors for gene therapy derive from adenoviruses, retroviruses, vaccinia virus, poxviruses, adeno-associated viruses, herpes simplex virus and lentiviruses [73] . In the context of cancer stem cells which can remain quiescent for long periods [74] , the latter represents a promising newcomer as a gene transfer vector due to its abilities to efficiently and stably transduce non-dividing cells.
Along with these replication-defective viral vectors, replicative-competent viruses, able to replicate selectively in tumor cells with specified oncogenic phenotypes have been used [75] .
These oncolytic viruses can be either naturally occurring or modified to obtain tumor specificity and can be adapted as vectors for cancer gene therapy. particularly when compared to viral vectors, and the considerable reduction of their biological activity by serum components [78] . Moreover, systemic administration of lipoplexes can result in some toxicity, most probably due to their positive charge and propensity to aggregate, which also limits their clinical application [81] . However, the potential advantages of these systems over viral vectors encouraged investigators to further improve their performance by developing novel formulations. In this regard, much effort has been devoted to the synthesis of numerous novel cationic lipids and polymers, which could improve the stability and efficiency of their complexes with nucleic acids; incorporation of hydrophilic components, such as polyethylene glycol (PEG), which could mask the positive charge of the complexes, thus increasing their circulation time in blood stream and reducing toxicity; and association of proteins, antibodies, peptides or other agents that could enhance the biological activity and specificity to target cells [81; 82; 83; 84] . Therefore, it is expected that in a near future the improvements performed in non-viral gene delivery systems will result in the generation of vectors that fulfill the standard requirements for clinical use in terms of efficiency and specificity, namely for systemic administration.
Non-viral vectors
Cellular vehicles
Various 
"Unconventional" vectors
In this section we summarize newly developed vectors including both non-viral biological agents exhibiting natural properties that can be exploited for specific tumor gene delivery andnanovectors that appear as promising tools due to their size and supramolecular structure.
Non-viral biological gene delivery vehicles include bacteria, bacteriophages, virus-like particles, erythrocyte ghosts, and exosomes (reviewed in, [88] Due to the unique properties of nano-scale matter, nanoparticle-based delivery systems have also emerged as potential gene carriers [94] . These vectors can enhance tumor accumulation of the carried biologically active agent due to the so-called enhanced permeability and retention effect (EPR effect). This effect results from the combination of an increased permeability of tumor blood vessels and a decreased rate of clearance within the tumor [95] .
As a consequence, nanocarriers passively accumulate in solid tumors after their intravenous administration. This type of vectors is presently used more often for siRNA than for plasmid DNA delivery.
Tracing vector biodistribution and transgene expression by non-invasive molecular imaging
Whatever the vector used, monitoring vector biodistribution and transgene expression remains a critical issue in gene therapy protocols. One of the advantages of suicide gene therapy is that the therapeutic gene can also be used as reporter gene for non-invasive imaging to determine the distribution, magnitude and kinetics of vector-mediated gene expression. The most commonly used reporter gene for small-animal molecular imaging studies using radiolabelled probes and positron-emission tomography is HSV-TK [96; 97] . Indeed, like GCV, The CD-mediated conversion of 5-FC to 5-FU can also be quantified in vivo using magnetic resonance spectroscopy [101] . The same method was used to demonstrate that the therapeutic efficiency is enhanced by combining CD and UPRT, which improves the conversion of 5-FC to toxic metabolites [102] . Altogether, research in this field should lead to a better understanding of suicide gene therapy at the molecular level, allowing improving the efficacy and safety of current clinical protocols.
Bystander effects and mechanisms
Suicide gene therapy is associated with two distinct bystander effects. 
Local bystander effect
One of the main advantages of the CD/5-FC system is the strong local bystander effect that Local bystander effect has also been observed by using cellular vehicles expressing a suicide gene. Mouse embryonic endothelial progenitor cells, which home preferentially to hypoxic lung metastases when administered intravenously, were shown to exert a local bystander effect on lung tumor cells in vitro and in vivo upon CD gene expression followed by 5-FC treatment [108] . Human adipose tissue-derived mesenchymal stem cells (ATMSC) were also used as a vehicle for the CD gene and were able of tumor targeting and growth inhibition after systemic administration and 5-FC treatment [39; 40] . Similarly, multiple transplantations of CD-expressing MSCs in established C6 brain tumors, followed by 5-FC treatment, were able to successfully repress tumor growth [109] . Neural stem cells, which exhibit an extensive tumor tropism, were also shown to be an efficient vehicle for the CD gene in a glioma animal model [110] . Finally, mutant forms of bacterial CD were recently described to significantly improve 5-FC cell sensitization and bystander effect compared with wild-type CD [111] .
A significant anti-tumor effect was also induced by GCV in tumors containing 50% HSV TKnegative and positive cells [107] . However, in contrast with FU, GCV triphosphate cannot passively diffuse to neighboring cells and local bystander effect was shown to be mediated by different mechanisms. It was first demonstrated that the bystander effect requires cell-to-cell contact, suggesting the passage of toxic GCV metabolites from TK-expressing cells to unmodified tumor cell [112] . The requirement of gap junctions was then evidenced by comparing the bystander effect in tumor cell lines transfected or not with connexin genes [113] , which was also revealed in human primary malignant glioma cell cultures [114] . In parallel, using flow cytometric and electron microscopic analysis, Freeman et al.
demonstrated that the bystander effect can also be mediated via apoptotic bodies generated from dying TK-expressing cells and phagocytosed by unmodified neighboring cells [103] .
Finally, some studies reported a gap junction-independent local bystander effect mediated by soluble factors, likely corresponding to phosphorylated GCV metabolites [115; 116] . More recently, the expression of E-cadherin, which is involved in the formation and function of gap junctions, was shown to correlate strongly with the TK/GCV bystander effect. The coexpression of TK and E-cadherin genes mediated by an adenoviral vector improved TK/GCV cytotoxicity and triggered a potent anti-tumor effect, superior to the one generated by an adenoviral vector expressing only TK. Moreover, the increased expression of E-cadherin was found to be associated to a decrease in the bcl-2 content, which suggests that a high Ecadherin content improved TK/GCV therapy by both enhancing the bystander effect and facilitating apoptosis induction [117] .
Several types of TK-expressing cellular vehicles have also been used to target tumor cells in vivo. Human adipose tissue mesenchymal stromal cells (AMSCs) expressing renilla luciferase and TK were used as cellular autologous delivery vehicles for GCV-mediated bystander killing of firefly luciferase-expressing tumors [118] . By using a non-invasive bioluminescence imaging to continuously monitor both tumor cells and AMSCs, the authors showed a significant bystander killing in mice bearing prostate tumors after treatment with therapeutic AMSCs and GCV [118] .
As AMSCs, neural stem cells (NSCs) were also used as a cellular therapeutic delivery system In a clinical trial, 27 patients undergoing malignant glioma resection were injected with murine retroviral vector producer cells (VPCs) for HSV-TK suicide gene therapy. Local inflammation and devascularisation were the mechanisms responsible for the observed bystander effect in this type of tumor [123] .
Finally, it is of interest to note that Wilson et al. developed a physiologically relevant tissue culture model for quantifying local bystander effect in vitro by using three-dimensional (3D) multilayer co-cultures of transduced and non-transduced cells. They used nitroreductase (NTR) gene-dependent enzyme-prodrug therapy to show that the local bystander effect was underestimated in 2D-culture and the 3D-culture system appears as a valuable tool to quantify and optimize bystander effects [43] .
Distant bystander effect
The other effect associated to suicide gene therapy, named distant bystander effect, consists in the regression of WT tumors distant from those expressing the suicide gene. Regression of untransduced tumors growing at a distance from transduced tumors is well documented in the TK/GCV system [104; 124; 125; 126; 127] . Several hypotheses have been proposed to explain the TK-related distant anti-tumor effect. The involvement of the immune system was proposed in most studies, based on the presence of T lymphocyte infiltrates within the tumors [104; 125; 126; 127] . However, a distant bystander effect was also detected in immunodeficient SCID mice, which suggests that alternative mechanisms may be operating, such as the release of a soluble factor that might contribute to the observed distant anti-tumor effect [124] .
Regarding the CD/5-FC suicide system, we and others provided evidence for the existence of a distant bystander effect, which was observed after injection of CD-expressing tumor cells [68; 105; 128; 129] ; or after CD gene delivery via naked DNA injection [130] . Such an immune effect acting on pre-established wild-type tumors was dependent on both CD4+ and CD8+ lymphocytes as well as on natural killer cells [68; 105; 131] .
Suicide gene therapy in combination with other therapeutic strategies
The combination of CD/5-FC and HSV-TK/GCV suicide systems has resulted in enhanced anti-tumor activity in vitro [132; 133] and in vivo [133] . In this regard, it was shown that sequential prodrug treatment was more efficient than their simultaneous addition as CD/5-FCmediated reduction of dTTP results in a concurrent decrease of dGTP, which is the endogenous competitor of GCV triphosphate [133] . The combination of suicide gene therapy with conventional chemotherapy was also shown to result in a great antitumoral activity, both in vitro [146; 147; 148; 149] and in vivo [146; 147; 148] . The additional combination with RNAi-based gene therapy was found to be more efficient when compared to each therapy application alone [150] . These authors developed a novel delivery system combining HSV-tk gene with MDR1 shRNA cassette and were able to show enhanced cell sensitivity to anti-cancer drugs [150] . fusion gene between endostatin and CD followed by 5-FC treatment was more efficient and less toxic than the combination of an antibody against VEGF-A (Bevacizumab) and 5-FU in human breast and colorectal orthotopic animal models [160] . Suicide gene therapy is also frequently used in adoptive transfer strategies. This approach, which consists in the transfer of gene-modified T cells, is able to mediate tumor regression in patients with metastatic cancer [162] . However, the adoptive cell therapy may lead to severe autoimmune reaction or to the occurrence of graft-versus-host disease (GvHD), limiting the clinical application of this strategy. In the case of severe GvHD, transfer of a suicide gene into infused T cells appears as a safety switch preserving the antitumoral effect and enabling the destruction of donor T cells.
In this regard, several suicide systems have been used such as HSV-TK/GCV, either alone [163] or associated with other transgenes stimulating alloreactivity [22] , CD20/anti-CD20 antibody rituximab [164] , and an inducible caspase 9 that is activated using a specific chemical inducer of dimerization [165; 166] .
Finally, it is important to mention that nanocarriers have emerged as ideal platforms for achieving multi-functionalization and appear as optimal vectors for application of combined strategies [94] . This is examplified in a study of Li et al. describing the use of a nanoplex carrying magnetic resonance imaging reporters for in vivo detection and optical reporters for microscopy, to image the delivery of siRNA and a functional prodrug enzyme into breast tumors towards an image-guided molecular targeted cancer therapy [167] .
Future directions
Recent literature about suicide gene therapy for cancer treatment clearly shows that this field is still under intense investigation. The use of new delivery vectors together with the therapeutic strategies described above have significantly improved the efficiency of suicide gene therapy.
The majority of cancers remain resistant to the current therapeutic options and it recently appeared that CSCs could be one of the key determinants of treatment failure [2; 74] .
Therefore, CSCs are now considered as a new promising target for therapeutic approaches aiming at improving the clinical cancer therapy field. CSCs express various molecules protecting them from cytotoxic agents such as ATP-binding cassette (ABC) transporters which actively efflux drugs from cells [168] . In addition, these cells can exhibit a relative quiescence, possess an active DNA-repair capacity and resistance to apoptosis which make them resistant to classical drug-based therapies [169] . However, we can hypothesize that an in situ continuous lethal drug production by CSCs themselves should be more effective than the systemic exposure to the drug. Indeed, in a quiescent state, CSCs should behave as drug-producing cells which, within a tumor, should eliminate their differentiated progeny. Therefore, it is expected that upon division, suicide gene-expressing CSCs will die.
Indeed, in a glioma nude rat model generated by CSC spheroids derived from patient biopsies, 
